Gyejigachulbutang (Gui-Zhi-Jia-Shu-Fu-Tang, Keishikajutsubuto, TJ-18) in Degenerative Knee Osteoarthritis Patients: Lessons and Responders from a Multicenter Randomized Placebo-Controlled Double-Blind Clinical Trial

Table 5

Analysis of participants with BMI 25 or more and BMI less than 25 (N = 80).

VAS	BMI 25 or more (n = 43)			BMI less than 25 (n = 37)
	GCB group^†	Placebo group^†	value^‡	GCB group^†	Placebo group^†	value^‡
Baseline	56.52 (49.44, 63.60)	55.45 (47.08, 63.82)	0.8675	59.88 (49.29, 70.47)	65.15 (56.49, 73.81)	0.7951
Week 2	54.26 (45.55, 62.97)	52.57 (42.39, 62.75)		50.24 (39.40, 61.07)	52.95 (43.22, 62.67)
Difference	−2.26 (−5.89, 1.06)	−2.88 (−6.13, 0.36)		−9.45 (−13.38, −5.92)	−12.20 (−15.03, 9.38)
value^a	0.1808	0.0812		<0.0001	<0.0001
Week 4	57.22 (48.35, 66.09)	56.40 (44.95, 67.86)	0.9434	49.71 (38.74, 60.67)	66.44 (57.07, 75.80)	0.0239
Difference	0.70 (−3.61, 5.00)	0.95 (−4.24, 6.14)		−10.18 (−15.06, −5.30)	1.29 (−1.64, 4.21)
value^a	0.7496	0.7166		<0.0001	0.3857
Week 8	48.33 (37.90, 58.77)	47.90 (38.04, 57.75)	0.9353	45.59 (32.46, 58.72)	52.45 (44.44, 60.46)	0.5772
Difference	−8.19 (−14.01, −2.37)	−7.55 (−13.20, −1.90)		−14.29 (−18.80, −9.79)	−12.70 (−16.73, −8.68)
value^a	0.0062	0.0093		<0.0001	<0.0001

^†Data expressed as 95% confidence interval. ^‡The mean difference was analyzed through analysis of covariance with the baseline score as covariant. ^ap value was calculated from the paired t-test, Significant difference. VAS, visual analogue scale. GCB, Gyejigachulbutang.